These and other studies unequivocally suggest that inhibiting astrocytic activation by pharmacological blockade of S100B biosynthesis may be a valuable therapeutic strategy to combat ischemic stroke and to delay onset and/or progression of AD. The gene discussed is S100B; the disease is Alzheimer disease.